Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Mostly true Scientifically well supported Certainty of evidence: moderate provisional C-BAR-08

The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).

Safety note: People with diabetes after bariatric surgery need continued glucose monitoring; medication must not be stopped without medical supervision.
In short: This claim is mostly correct: diabetes remission after bariatric surgery declines considerably over the years (for example 72% to 30% in SOS), but people who had surgery still did better than those on usual care, so relapse does not mean surgery failed.
Conclusion: Remission often fades, but surgery remains better than usual care for diabetes.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

أما هدوء السكري الذي تُرفع رايته، فيتآكل: في SOS انخفض من 72% بعد سنتين إلى 30% فقط بعد 15 سنة، وفي متابعة Adams لـ 12 سنة من 75% إلى 51%.

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).

Origin

Source status
Archive editors
Attribution
Archive editors (eltayebat.com); not necessarily Elawady's own words
Origin
https://eltayebat.com/rule/bariatric-surgery/
Attribution uncertainty
Editorial summary/narrative and study selection written by the archive operators; the archive states that the cited research documents harm independently of Dr. Diaa's words.
Claimed mechanism

Not specified.

Claimed health effect

Diabetes relapse.

Population concerned

People with type 2 diabetes and obesity

Geographic restriction by Elawady

not applicable

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

That diabetes remission erodes ('relapse within a few years').

2. What is demonstrably correct?

Correct that remission declines: SOS 72.3% -> 30.4% (A-BAR-23), Adams 75% -> 51% (A-BAR-04), LABS 71% -> 60% at 7 years (A-BAR-06), Mingrone 58.8% of early remitters relapsed (I-BAR-03), ARMMS 18.2% at 7 years and 12.7% at 12 years (I-BAR-02).

3. What is wrong or exaggerated?

'Within a few years' is exaggerated (declines are gradual over 7-15 years). The archive omits that control groups had far lower remission (SOS 6.5%; ARMMS 0%), that microvascular complications were halved (HR 0.44), that diabetes incidence fell by >90% and that 69% of patients in remission at 2 years remained diabetes-free at 12 years, with 12-year remission far higher than in non-operated controls (adjusted OR 8.9 and 14.8) (Adams, A-BAR-04), and that relapsers in Mingrone kept HbA1c around 6.7%. The Arabic SOS headline wrongly says 30.4% of initially remitted patients stayed in remission.

4. What remains unclear?

Long-term effect of modern procedures on hard outcomes.

5. Which studies support it?

A-BAR-04, A-BAR-06, A-BAR-23, I-BAR-02, I-BAR-03; long-term relapse about 30% after bypass (I-BAR-131); 5-year relapse 33% (bypass) and 42% (sleeve) among remitters (I-BAR-134); Oseberg 5-year remission only 50% (bypass) and 20% (sleeve) (I-BAR-116).

6. Which studies contradict it?

A-BAR-24, A-BAR-23 (complications), I-BAR-03 (glycaemic control), I-BAR-02; network meta-analysis of 36 RCTs showing more remission and lower HbA1c with surgery than medical therapy (I-BAR-132); fewer microvascular complications (I-BAR-133). The 2026 Cochrane review (I-BAR-143) rates long-term RCT evidence on complete remission as very uncertain.

7. What applies to Germany and Europe?

Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.

8. What is known about Egypt?

No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.

9. What practical conclusion is appropriate?

Remission is not permanent for many; continued diabetes monitoring after surgery is needed. Relapse does not cancel the comparative benefit.

Assessment details

Rationale for certainty of evidence

Consistent across cohorts and RCTs that remission declines; equally consistent that surgery remains superior to medical therapy.

Source quality

Numbers correct; framing selective (controls and complication reduction not mentioned); Arabic headline misstates the 30.4% denominator.

Regional transferability

European RCT and SOS data.

Individual exceptions

Relapse more likely with longer diabetes duration and weight regain (general knowledge; not quantified here).

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

Scientifically well supported – The claim agrees with consistent, high-quality evidence.

Research question: In people with type 2 diabetes, does remission after bariatric surgery decline over time, and how does this compare with medical therapy?

Research question in detail (PICO)
Population
Adults with type 2 diabetes and obesity
Intervention or exposure
Bariatric surgery
Comparison
Medical/lifestyle therapy; early vs late follow-up
Geographic scope
universal biology
Outcomes
  • Diabetes remission
  • Relapse
  • HbA1c
  • Microvascular complications

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Remission erodes substantially over years (the archive numbers are correct), but surgery still keeps better glycaemic control and fewer complications than medical therapy on average.

Why some studies weigh more

RCTs and SOS long-term data; Cochrane review sets limits on certainty.

Is a causal relationship established? Yes, established Relapse is linked to weight regain and diabetes duration; RCTs confirm surgery superiority short-to-medium term.

Remaining uncertainty

Effect of modern procedures on hard outcomes over decades.

Justified conclusion

Mostly true as stated; incomplete as an argument against surgery.

Why do studies seem to disagree?

No real conflict: erosion of remission over time and superiority over medical therapy are both shown by the same studies.

Does this depend on the country?
General biological effects
Universal.
Eating habits
Diet after surgery influences relapse.
Origin of the food
Not applicable (surgical procedure, not a food).
Contaminants
Not applicable (surgical procedure, not a food).
National production conditions
Not applicable.
Legal rules
Not applicable.
Actual monitoring data
No Egyptian data found.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • CI symmetry; illustrative share in remission at 5 years – HRs symmetric; illustrative remission at 5 y ~58% (RYGB) and ~49% (SG) after accounting for relapse (ignores timing). recalculated
  • Reproduce 5-y remission risk differences – RD 29.5% and 33.5% reproduced from counts. recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Durability of diabetes remission after surgery
Starting level
high (randomised trials)
Reasons for downgrading
  • imprecision (small long-term RCTs)
Result
moderate

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked
  • ADA: Standards of Care in Diabetes-2026, Section 8 (I-DIAB-113) (2026) · Original publication
    Consider metabolic surgery in type 2 diabetes with BMI >=30 (>=27.5 Asian American) (A); long-term medical and behavioural support with routine micronutrient and metabolic monitoring (B); routine psychosocial screening after surgery (C); text cites lower relapse after RYGB than sleeve (5-y relapse 33.1% vs 41.6%).
Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026(TITLE:"diabetes") AND (TITLE:"relapse" OR TITLE:"recurrence" OR TITLE:"long-term remission" OR TITLE:"durability") AND (TITLE:"bariatric" OR TITLE:"metabolic surgery" OR TITLE:"sleeve" OR TITLE:"gastric bypass") AND (PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis" OR TITLE:"randomized" OR TITLE:"randomised")supporting evidence2
PubMed26 October 2026(bariatric surgery[ti] OR gastric bypass[ti] OR sleeve gastrectomy[ti]) AND type 2 diabetes AND (relapse[ti] OR recurrence[ti]) AND 2019:2026[dp]supporting evidence27
Europe PMC26 October 2026(TITLE:"metabolic surgery" OR TITLE:"bariatric surgery") AND (TITLE:"medical therapy" OR TITLE:"medical treatment") AND TITLE:"type 2 diabetes" AND (TITLE:"long-term" OR TITLE:"10-year" OR TITLE:"12-year" OR TITLE:"meta-analysis") AND PUB_YEAR:[2020 TO 2026]contradicting evidence4
PubMed26 October 2026(metabolic surgery[ti] OR bariatric surgery[ti]) AND (medical therapy[tiab] OR medical treatment[tiab]) AND type 2 diabetes[ti] AND (meta-analysis[pt]) AND randomized AND 2019:2026[dp]contradicting evidence9
PubMed26 October 2026"Obesity and Weight Management for the Prevention and Treatment of Diabetes" AND Standards of Care in Diabetesguidelines80
Europe PMC26 October 2026JOURNAL:"Cochrane Database Syst Rev" AND (TITLE:"surgery for weight loss" OR TITLE:"bariatric" OR TITLE:"obesity surgery" OR TITLE:"surgery for obesity")guidelines13
PubMed26 October 2026McTigue KM[au] AND sleeve gastrectomy AND gastric bypass AND diabetes AND JAMA Surg[ta]both directions2

Open questions

Predictors of durable remission; long-term outcomes of sleeve vs bypass in Egyptian patients.

How deeply was this checked?

13 linked studies: 3 checked in full text (2 of them with a structured risk-of-bias assessment), 10 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Mostly true (moderate)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly true (moderate)
    Unchanged (“Mostly true”, moderate). New meta-analyses confirm relapse rates and surgery superiority; Cochrane review adds that long-term RCT certainty is low. Safety note preserved.
    New sources: I-BAR-116 I-BAR-131 I-BAR-134 I-BAR-132 I-BAR-133 I-DIAB-113 I-BAR-143

In plain language

The archive says the diabetes benefit of weight-loss surgery fades. It is true that many people whose diabetes went into remission later relapse: in Sweden, remission fell from 72% at two years to 30% at 15 years. But people without surgery did much worse (only 6.5% in remission), and diabetes complications were about halved after surgery. So relapse is common, but surgery still kept an advantage over usual care.

Studies on this claim

Studies supporting the claim (6)

  • 12 years after gastric bypass

    Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459
    Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment★ key study

    Half of the patients with diabetes were still in remission after 12 years; new diabetes was about 90% less frequent than in non-operated people.

    The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Long-term outcomes

    How was the study done?

    Prospective controlled cohort

    How many people, animals or samples were studied?

    1156 adults

    What was actually found?

    Remission declines but benefit persists

    How large was the observed effect?

    Remission 51% at 12 y; incident T2D OR 0.08

    What do the results mean in everyday life?

    Relapse happens, but many stay in remission

    What are the study's limitations?

    Non-randomized; small diabetic subgroup; many controls later had surgery; mostly women in Utah

    What does it say about Elawady's specific claim?

    Relapse claim true; 'benefit erodes away' overstated

    Do the results apply to Germany and Europe?

    Applicable

    What can explicitly not be concluded from this study?

    Exact causal effect; outcomes for sleeve gastrectomy

    Scientific details →

  • 7 years after bypass or band

    Courcoulas AP et al.. JAMA Surg 2018 · PMID 29214306 · DOI 10.1001/jamasurg.2017.5025
    Cohort studycited by the Tayebat archiveabstract checked

    About 60% of bypass patients with diabetes were still in remission at 7 years.

    The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Durability

    How was the study done?

    Cohort

    How many people, animals or samples were studied?

    2348

    What was actually found?

    Remission 71%->60% (RYGB)

    How large was the observed effect?

    see results

    What do the results mean in everyday life?

    Most keep benefit, some relapse

    What are the study's limitations?

    No control

    What does it say about Elawady's specific claim?

    Partly supports erosion claim

    Do the results apply to Germany and Europe?

    Applicable

    What can explicitly not be concluded from this study?

    Comparison with non-surgical care

    Scientific details →

  • SOS: diabetes after 15 years

    Sjöström L et al.. JAMA 2014 · PMID 24915261 · DOI 10.1001/jama.2014.5988
    Cohort studycited by the Tayebat archiveabstract checked★ key study

    Remission fell from 72% at 2 years to 30% at 15 years after surgery (controls: 16% to 6.5%); diabetes complications were about halved.

    The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Diabetes long-term

    How was the study done?

    Prospective matched cohort

    How many people, animals or samples were studied?

    603 with T2D

    What was actually found?

    Remission declines; complications fewer

    How large was the observed effect?

    OR 6.3 at 15 y; HR 0.44 microvascular

    What do the results mean in everyday life?

    Relapse is common, but surgery still did better than usual care

    What are the study's limitations?

    Attrition; non-randomized

    What does it say about Elawady's specific claim?

    Relapse true; 'collapse' framing incomplete

    Do the results apply to Germany and Europe?

    European

    What can explicitly not be concluded from this study?

    Effect of modern procedures

    Scientific details →

  • Norwegian trial: bypass vs sleeve in type 2 diabetes

    Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6
    Randomised controlled trialindependent cross-checkabstract checked★ key study

    After 5 years, diabetes was in remission in 50% after bypass vs 20% after sleeve; acid reflux was more common after sleeve, but Barrett changes were similar.

    Remission at 5 y only 50% (RYGB) and 20% (SG).

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Compare RYGB and SG in T2D

    How was the study done?

    Randomised trial

    How many people, animals or samples were studied?

    109

    What was actually found?

    Bypass better for remission and weight; sleeve more acid reflux

    How large was the observed effect?

    RD 29.5%

    What do the results mean in everyday life?

    Bypass helps diabetes more but is not a cure

    What are the study's limitations?

    Small, single centre

    What does it say about Elawady's specific claim?

    Supports bypass preference for diabetes/reflux; contradicts "complete cure"

    Do the results apply to Germany and Europe?

    Directly European

    What can explicitly not be concluded from this study?

    Long-term hard outcomes

    Scientific details →

  • Meta-analysis: diabetes returning after bypass

    Yu et al.. Obes Surg 2021 · PMID 34505971 · DOI 10.1007/s11695-021-05692-4
    Meta-analysisindependent cross-checkabstract checked

    About 3 in 10 people whose diabetes went into remission after bypass later relapsed; relapse was less common than after sleeve.

    Long-term relapse ~30% after RYGB.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Relapse after RYGB

    How was the study done?

    Meta-analysis

    How many people, animals or samples were studied?

    17 studies

    What was actually found?

    Relapse 30%

    How large was the observed effect?

    HR 0.73 vs SG

    What do the results mean in everyday life?

    Remission is not always permanent

    What are the study's limitations?

    Observational

    What does it say about Elawady's specific claim?

    Supports erosion claim

    Do the results apply to Germany and Europe?

    Applicable

    What can explicitly not be concluded from this study?

    Effect on complications

    Scientific details →

  • US study: diabetes 5 years after bypass vs sleeve

    McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087
    Cohort studyindependent cross-checkabstract checked★ key study

    Diabetes remission was slightly more common and relapse less common after bypass; still, about 1 in 3 remitted bypass patients relapsed within 5 years.

    5-y relapse 33% (RYGB) and 42% (SG) among remitters.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Compare T2D outcomes RYGB vs SG

    How was the study done?

    Cohort

    How many people, animals or samples were studied?

    9,710

    What was actually found?

    Relapse 33% vs 42%

    How large was the observed effect?

    Relapse HR 0.75

    What do the results mean in everyday life?

    Bypass a bit better; neither is a guaranteed cure

    What are the study's limitations?

    Observational

    What does it say about Elawady's specific claim?

    Supports relapse claim; contradicts "complete cure"

    Do the results apply to Germany and Europe?

    Plausible

    What can explicitly not be concluded from this study?

    Hard outcomes

    Scientific details →

Studies contradicting or limiting the claim (3)

  • STAMPEDE: surgery vs medicines for diabetes

    Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869
    Randomised controlled trialcited by the Tayebat archivefull text, structured risk-of-bias assessment

    After 5 years, 23-29% of operated patients reached near-normal HbA1c vs 5% with medicines alone.

    The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Diabetes RCT

    How was the study done?

    RCT

    How many people, animals or samples were studied?

    150

    What was actually found?

    Surgery better

    How large was the observed effect?

    29%/23% vs 5%

    What do the results mean in everyday life?

    Surgery helps more, but most did not reach the target and only 15-22% reached it without diabetes medicines

    What are the study's limitations?

    Small single-centre trial; not blinded; more drop-outs in the medical group; ITT result not significant

    What does it say about Elawady's specific claim?

    Contradicts 'benefit erodes away'

    Do the results apply to Germany and Europe?

    Applicable

    What can explicitly not be concluded from this study?

    Hard outcomes

    Scientific details →

  • Network meta-analysis of trials: surgery vs medicines for diabetes

    De Luca et al.. Diabetes Obes Metab 2023 · PMID 37272316 · DOI 10.1111/dom.15117
    Meta-analysisindependent cross-checkabstract checked★ key study

    Across 36 trials, weight-loss operations led to more diabetes remission and lower blood sugar than medical treatment.

    RCTs show surgery superior to medical therapy for remission and HbA1c despite later relapse.

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Surgery vs medical therapy in T2D

    How was the study done?

    NMA of RCTs

    How many people, animals or samples were studied?

    36 RCTs

    What was actually found?

    Surgery better

    How large was the observed effect?

    not in abstract

    What do the results mean in everyday life?

    Surgery helps diabetes more than medicines alone

    What are the study's limitations?

    Short follow-up

    What does it say about Elawady's specific claim?

    Puts relapse in context

    Do the results apply to Germany and Europe?

    Applicable

    What can explicitly not be concluded from this study?

    Lifelong effect

    Scientific details →

  • Meta-analysis: eye and kidney damage in diabetes after surgery

    Obeso-Fernández et al.. Surg Obes Relat Dis 2023 · PMID 37169666 · DOI 10.1016/j.soard.2023.02.024
    Meta-analysisindependent cross-checkabstract checked

    People with diabetes who had surgery had fewer eye and kidney complications than those treated with medicines alone.

    Lower microvascular complications after surgery.

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Microvascular outcomes

    How was the study done?

    Meta-analysis

    How many people, animals or samples were studied?

    160,072

    What was actually found?

    Less retinopathy, nephropathy, ESRD

    How large was the observed effect?

    OR 0.29-0.41

    What do the results mean in everyday life?

    Benefit even if diabetes returns

    What are the study's limitations?

    Observational

    What does it say about Elawady's specific claim?

    Context for relapse

    Do the results apply to Germany and Europe?

    Applicable

    What can explicitly not be concluded from this study?

    Causation

    Scientific details →

Studies with mixed or unclear results (4)

  • Diabetes 12 years after randomized surgery vs medicine

    Courcoulas AP et al.. JAMA 2024 · PMID 38411644 · DOI 10.1001/jama.2024.0318
    Randomised controlled trialindependent cross-checkabstract checked★ key study

    Blood sugar control stayed better after surgery; full remission was uncommon in both groups but more frequent after surgery (12.7% vs 0%).

    The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Long-term T2D

    How was the study done?

    Pooled RCT follow-up

    How many people, animals or samples were studied?

    262

    What was actually found?

    Surgery better; remission declines

    How large was the observed effect?

    HbA1c -1.1% at 12 y

    What do the results mean in everyday life?

    Relapse is common, but surgery keeps an advantage

    What are the study's limitations?

    Crossover, small

    What does it say about Elawady's specific claim?

    Partly supports erosion; contradicts 'no benefit'

    Do the results apply to Germany and Europe?

    Applicable

    What can explicitly not be concluded from this study?

    Mortality

    Scientific details →

  • Italian 10-year diabetes surgery trial

    Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0
    Randomised controlled trialindependent cross-checkabstract checked★ key study

    More than half of those in remission at 2 years relapsed, but their sugar control stayed good (HbA1c 6.7%) and complications were fewer than with medicines alone.

    The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Durability

    How was the study done?

    RCT

    How many people, animals or samples were studied?

    60

    What was actually found?

    Relapse frequent; control better

    How large was the observed effect?

    RR complications 0.07

    What do the results mean in everyday life?

    Relapse does not mean the benefit is lost

    What are the study's limitations?

    Tiny

    What does it say about Elawady's specific claim?

    Partly supports

    Do the results apply to Germany and Europe?

    European

    What can explicitly not be concluded from this study?

    Generalizability

    Scientific details →

  • US diabetes standards 2026: weight loss and type 2 diabetes

    American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358882 · DOI 10.2337/dc26-S008
    Guideline / position statementindependent cross-checkfull text checked★ key study

    Losing more than 10% of body weight can lead to remission of type 2 diabetes and reduce the need for insulin.

    Endorses surgery while acknowledging relapse; requires ongoing monitoring.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Guide weight management.

    How was the study done?

    Guideline.

    How many people, animals or samples were studied?

    Not applicable.

    What was actually found?

    Weight loss >10% may induce remission.

    How large was the observed effect?

    Not applicable.

    What do the results mean in everyday life?

    Weight loss is a powerful treatment for type 2 diabetes.

    What are the study's limitations?

    Guideline.

    What does it say about Elawady's specific claim?

    Supports the T2D kernel of C-DIAB-03.

    Do the results apply to Germany and Europe?

    European guidance agrees.

    What can explicitly not be concluded from this study?

    Not applicable to T1D.

    Scientific details →

  • Cochrane review: surgery for obesity with type 2 diabetes

    Kiesswetter et al.. Cochrane Database Syst Rev 2026 · PMID 42610488 · DOI 10.1002/14651858.CD015622.pub2
    Meta-analysisindependent cross-checkabstract checked★ key study

    Trials show more weight loss and better blood sugar after surgery, but long-term data on complete diabetes remission, serious harms and deaths are very uncertain.

    Long-term complete remission very uncertain in RCTs; HbA1c and partial remission improved.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Benefits/harms of MBS in T2D

    How was the study done?

    Cochrane NMA

    How many people, animals or samples were studied?

    15,282

    What was actually found?

    Weight and HbA1c better; remission/mortality very uncertain

    How large was the observed effect?

    RYGB weight MD -17%

    What do the results mean in everyday life?

    Surgery helps, but long-term certainty is limited

    What are the study's limitations?

    Few RCT participants

    What does it say about Elawady's specific claim?

    Partly supports erosion claim; does not show harm

    Do the results apply to Germany and Europe?

    Applicable

    What can explicitly not be concluded from this study?

    Precise long-term effects

    Scientific details →

Regional context

Germany / EU

Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.

Egypt

No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.

What applies in my country?

General scientific assessment

Mostly true Remission often fades, but surgery remains better than usual care for diabetes.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Weight and Metabolic Outcomes 12 Years after Gastric Bypass.. Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459
  2. Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study.. Courcoulas AP et al.. JAMA Surg 2018 · PMID 29214306 · DOI 10.1001/jamasurg.2017.5025
  3. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.. Sjöström L et al.. JAMA 2014 · PMID 24915261 · DOI 10.1001/jama.2014.5988
  4. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.. Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6
  5. Meta-analysis of Long-Term Relapse Rate of Type 2 Diabetes Following Initial Remission After Roux-en-Y Gastric Bypass.. Yu et al.. Obes Surg 2021 · PMID 34505971 · DOI 10.1007/s11695-021-05692-4
  6. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study.. McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087
  7. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.. Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869
  8. Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta-analysis and network meta-analysis of randomized controlled trials.. De Luca et al.. Diabetes Obes Metab 2023 · PMID 37272316 · DOI 10.1111/dom.15117
  9. Benefits of bariatric surgery on microvascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis.. Obeso-Fernández et al.. Surg Obes Relat Dis 2023 · PMID 37169666 · DOI 10.1016/j.soard.2023.02.024
  10. Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes.. Courcoulas AP et al.. JAMA 2024 · PMID 38411644 · DOI 10.1001/jama.2024.0318
  11. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.. Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0
  12. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358882 · DOI 10.2337/dc26-S008
  13. Metabolic and bariatric surgery in adults with obesity and diabetes mellitus: a network meta-analysis.. Kiesswetter et al.. Cochrane Database Syst Rev 2026 · PMID 42610488 · DOI 10.1002/14651858.CD015622.pub2

← Back to overview